基于上皮间质转化探讨骨肉瘤恶性生物学行为相关研究进展

doi:10.3760/cma.j.cn371439-20251128-00071

国际肿瘤学杂志 ›› 2026, Vol. 53 ›› Issue (7): 439-444.doi: 10.3760/cma.j.cn371439-20251128-00071

基于上皮间质转化探讨骨肉瘤恶性生物学行为相关研究进展

张天焘¹, 徐世红², 王培鑫¹, 王小强¹, 李楷¹, 赵军¹()

¹ 甘肃中医药大学第一附属医院创伤中心，兰州 730050
² 甘肃中医药大学中医临床学院，兰州 730000

收稿日期:2025-11-28 出版日期:2026-07-08 发布日期:2026-06-29
通讯作者: 赵军，Email： 673078008@qq.com
基金资助:
国家自然科学基金(82560952);国家自然科学基金(82260945);甘肃省自然科学基金(25JRRA282);甘肃省自然科学基金(26JRRA769);兰州市科技局科技计划(2025-2-195);甘肃省中医药管理局高水平重点项目(GZKZ-2025-7)

Research progress on the malignant biological behavior of osteosarcoma based on epithelial-mesenchymal transition

Zhang Tiantao¹, Xu Shihong², Wang Peixin¹, Wang Xiaoqiang¹, Li Kai¹, Zhao Jun¹()

¹ Trauma Center， First Affiliated Hospital of Gansu University of Chinese Medicine， Lanzhou 730050， China
² College of Clinical Chinese Medicine， Gansu University of Chinese Medicine， Lanzhou 730000， China

Received:2025-11-28 Online:2026-07-08 Published:2026-06-29
Contact: Zhao Jun， Email： 673078008@qq.com
Supported by:
National Natural Science Foundation of China(82560952);National Natural Science Foundation of China(82260945);Natural Science Foundation of Gansu Province of China(25JRRA282);Natural Science Foundation of Gansu Province of China(26JRRA769);Lanzhou Science and Technology Bureau Science and Technology Project of China(2025-2-195);Gansu Provincial Administration of Traditional Chinese Medicine High-Level Key Project of China(GZKZ-2025-7)

摘要/Abstract

摘要：

骨肉瘤是青少年最常见的原发性恶性骨肿瘤，侵袭性强、预后不佳，尽管诊疗手段不断丰富，患者生存率仍未见显著提升，因此深入解析其发生发展机制尤为迫切。上皮间质转化（EMT）是驱动其恶性进展的核心生物学过程，通过促进肿瘤细胞迁移、侵袭、增殖，诱导肿瘤干细胞特性及化疗抵抗，进而影响患者预后。然而，EMT的动态可逆性、肿瘤内异质性以及现有体外/体内模型的局限性，制约了其临床转化应用，深入解析其调控机制，通过靶向抑制EMT在骨肉瘤中的表观遗传、肿瘤微环境及关键信号通路等方式，有望突破骨肉瘤治疗瓶颈，为克服肿瘤转移与耐药提供新方向，最终改善患者预后。

关键词: 上皮-间质转化, 骨肉瘤, 肿瘤微环境, 肿瘤转移, 药物耐受性

Abstract:

Osteosarcoma is the most common primary malignant bone tumor in adolescents， characterized by strong invasiveness and poor prognosis. Despite continuous advances in diagnostic and therapeutic methods， patient survival rates have not shown significant improvement， making it particularly urgent to deeply elucidate the mechanisms underlying its occurrence and progression. Epithelial-mesenchymal transition （EMT） is a core biological process driving the malignant progression of osteosarcoma， influencing patient prognosis by promoting tumor cell migration， invasion， and proliferation， inducing cancer stem cell characteristics and chemotherapy resistance. However， the dynamic reversibility of EMT， the intratumoral heterogeneity， and the limitations of current in vitro/in vivo models constrain its clinical translation and application. Nevertheless， in-depth analysis of its regulatory mechanisms and targeted inhibition of EMT through epigenetic modulation， tumor microenvironment intervention， and key signaling pathway blockade in osteosarcoma hold promise for breaking through therapeutic bottlenecks， providing new directions for overcoming tumor metastasis and drug resistance， and ultimately improving patient prognosis.

Key words: Epithelial-mesenchymal transition, Osteosarcoma, Tumor microenvironment, Neoplasm metastasis, Drug tolerance

张天焘, 徐世红, 王培鑫, 王小强, 李楷, 赵军. 基于上皮间质转化探讨骨肉瘤恶性生物学行为相关研究进展[J]. 国际肿瘤学杂志, 2026, 53(7): 439-444.

Zhang Tiantao, Xu Shihong, Wang Peixin, Wang Xiaoqiang, Li Kai, Zhao Jun. Research progress on the malignant biological behavior of osteosarcoma based on epithelial-mesenchymal transition[J]. Journal of International Oncology, 2026, 53(7): 439-444.

参考文献 47

[1]	Guo Q, Zhang N, Liu S, et al. By targeting TRAF6, miR-140-3p inhibits TGF-β1-induced human osteosarcoma epithelial-to-mesen-chymal transition, migration, and invasion[J]. Biotechnol Lett, 2020, 42(11): 2123-2133. DOI: 10.1007/s10529-020-02943-9.
[2]	Liu P, Wang W, Zhang H, et al. Long non-coding RNAs in osteosarcoma: multifaceted regulators of malignancy and therapeutic resistance[J]. J Transl Med, 2025, 24: 107. DOI: 10.1186/s12967-025-07564-2.
[3]	李青山, 郭红生, 贾天阳. ISLR通过活化PI3K-AKT通路促进上皮-间质转化影响骨肉瘤细胞恶性进展研究[J]. 现代检验医学杂志, 2024, 39(5): 17-21+29. DOI: 10.3969/j.issn.1671
[4]	Luo FC, Ando K, Takemura Y, et al. Epithelial-mesenchymal transition in osteosarcoma as a key driver of pulmonary metastasis[J]. Cancers, 2025, 17(17): 2922. DOI: 10.3390/cancers17172922.
[5]	Takeda T, Tsubaki M, Genno S, et al. RANK/RANKL axis promotes migration, invasion, and metastasis of osteosarcoma via activating NF-κB pathway[J]. Exp Cell Res, 2024, 436(2): 113978. DOI: 10.1016/j.yexcr.2024.113978.
[6]	周文彬, 单冰晨, 陈建生, 等. 长链非编码RNA linc-ITGB1对骨肉瘤细胞上皮间质转化和Wnt通路的影响[J]. 临床肿瘤学杂志, 2021, 26(8): 694-699. DOI: 10.3969/j.issn.1009-0460.2021.08.004.
[7]	Zhang HY, Huang YM, Wen QT, et al. INHBA gene silencing inhibits proliferation, migration, and invasion of osteosarcoma cells by repressing TGF-β signaling pathway activation[J]. J Orthop Surg Res, 2023, 18(1): 848. DOI: 10.1186/s13018-023-04330-2. pmid: 37940978
[8]	Lin DF, Shen LS, Luo M, et al. Circulating tumor cells: biology and clinical significance[J]. STTT, 2021, 6: 404. DOI: 10.1038/s41392-021-00817-8.
[9]	Li YX, Liu FS, Cai QJ, et al. Invasion and metastasis in cancer: molecular insights and therapeutic targets[J]. STTT, 2025, 10: 57. DOI: 10.1038/s41392-025-02148-4.
[10]	Tang F, Tie Y, Lan TX, et al. Surgical treatment of osteosarcoma induced distant pre-metastatic niche in lung to facilitate the colonization of circulating tumor cells[J]. Adv Sci, 2023, 10(28): e2207518. DOI: 10.1002/advs.202207518.
[11]	Dhawan U, Wang WL, Lin YC, et al. Mechanostimulation-induced integrin α_vβ₆ and latency associated peptide coupling activates TGF-β and regulates cancer metastasis and stemness[J]. Nano Today, 2023, 50: 101882. DOI: 10.1016/j.nantod.2023.101882.
[12]	Zheng XJ, Wu W, Zhao ZG, et al. Single-cell transcriptomic insights into chemotherapy-induced remodeling of the osteosarcoma tumor microenvironment[J]. J Clin Oncol, 2024, 150: 356. DOI: 10.1007/s00432-024-05787-2.
[13]	Garcia-ortega DY, Cabrera-nieto SA, Caro-sánchez HS, et al. An overview of resistance to chemotherapy in osteosarcoma and future perspectives[J]. Cancer Drug Resist, 2022, 5(3): 762-793. DOI: 10.20517/cdr.2022.18.
[14]	Gong HL, Tao Y, Xiao S, et al. Identification of an EMT-related gene-based prognostic signature in osteosarcoma[J]. Cancer Med, 2023, 12(11): 12912-12928. DOI: 10.1002/CAM4.5942.
[15]	Ni C, Sun QW, Yin HB. Comprehensive multi-omics analysis of histone acetylation modulators identifies ASH1L as a novel aggressive marker for osteosarcoma[J]. Discov Oncol, 2025, 16(1): 1070. DOI: 10.1007/s12672-025-02920-6. pmid: 40504347
[16]	Baron M, Drohat P, Crawford B, et al. Mesenchymal stem/stromal cells: immunomodulatory and bone regeneration potential after tumor excision in osteosarcoma patients[J]. Bioengineering (Basel), 2023, 10(10): 1187. DOI: 10.3390/bioengineering10101187.
[17]	Zeng J, Peng Y, Wang D, et al. The interaction between osteosarcoma and other cells in the bone microenvironment: from mechanism to clinical applications[J]. Front Cell Dev Biol, 2023, 11: 1123065. DOI: 10.3389/fcell.2023.1123065.
[18]	Yu X, Yustein JT, Xu J. Research models and mesenchymal/epithelial plasticity of osteosarcoma[J]. Cell Biosci, 2021, 11(1): 94. DOI: 10.1186/s13578-021-00600-w. pmid: 34022967
[19]	Tian YH, Liu RJ, Hou XY, et al. SIRT₂ promotes the viability, invasion and metastasis of osteosarcoma cells by inhibiting the degradation of snail[J]. Cell Death Dis, 2022, 13(11): 935. DOI: 10.1038/s41419-022-05388-2.
[20]	Ruh M, Stemmler MP, Frisch I, et al. The EMT transcription factor ZEB1 blocks osteoblastic differentiation in bone development and osteosarcoma[J]. J Pathol, 2021, 254(2): 199-211. DOI: 10.1002/path.5659.
[21]	Liu M, Wang D, Li N. MicroRNA-20b Downregulates HIF-1α and inhibits the proliferation and invasion of osteosarcoma cells[J]. Oncol Res, 2016, 23(5): 257-266. DOI: 10.3727/096504016X14562725373752. pmid: 27098149
[22]	Zhang ML, Zhang B. Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer[J]. Exp HematoL Oncol, 2025, 14: 54. DOI: 10.1186/s40164-025-00647-2. pmid: 40211368
[23]	Luu AK, Viloria-petit AM. Targeting mechanotransduction in osteosarcoma: a comparative oncology perspective[J]. Int J Mol Sci, 2020, 21(20): 7595. DOI: 10.3390/ijms21207595.
[24]	Cui JC, Dean D, Hornicek FJ, et al. The role of extracelluar matrix in osteosarcoma progression and metastasis[J]. J Exp Clin Canc Res, 2020, 39: 178. DOI: 10.1186/s13046-020-01617-4.
[25]	Palmer EP, Cronise KE, Haines LA, et al. Osteosarcoma exosome priming of primary human lung fibroblasts induces an immune modulatory and protumorigenic phenotype[J]. Cancer Res Commun, 2025, 5(4): 594-608. DOI: 10.1158/2767-9764.CRC-24-0371.
[26]	Chong ZX, Yeap SK, Ho WY. Unraveling the roles of miRNAs in regulating epithelial-to-mesenchymal transition (EMT) in osteosarcoma[J]. Pharmacol Res, 2021, 172: 105818. DOI: 10.1016/j.phrs.2021.105818.
[27]	Shi QY, Xu JH, Chen CL, et al. Direct contact between tumor cells and platelets initiates a FAK-dependent F3/TGF-β positive feedback loop that promotes tumor progression and EMT in osteosarcoma[J]. Cancer Lett, 2024, 591: 216902. DOI: 10.1016/j.canlet.2024.216902.
[28]	Wang JY, Yang Y, Ma YJ, et al. Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma[J]. Biomed Pharmacother, 2020, 121: 109627. DOI: 10.1016/j.biopha.2019.109627.
[29]	陈敬腾, 余铃, 方硕, 等. Notch信号通路可通过激活Slug调控骨肉瘤上皮-间质转化[J]. 肿瘤防治研究, 2020, 47(1): 6-12. DOI: 10.3971/j.issn.1000-8578.2020.19.0704.
[30]	Deng JY, Yi X, Feng ZX, et al. Deubiquitinating enzyme USP10 promotes osteosarcoma metastasis and epithelial-mesenchymal transition by stabilizing YAP1[J]. Cancer Med, 2023, 12(13): 14452-14467. DOI: 10.1002/cam4.6074.
[31]	Lu Y, Cao GL, Lan HY, et al. Chondrocyte-derived exosomal miR-195 inhibits osteosarcoma cell proliferation and anti-apoptotic by targeting KIF4A in vitro and in vivo[J]. Transl Oncol, 2022, 16: 101289. DOI: 10.1016/j.tranon.2021.101289.
[32]	Bao ZQ, Cheng ZN, Chai DM. The expressions of CD133, ALDH1, and vasculogenic mimicry in osteosarcoma and their clinical significance[J]. Int J Clin Exp Pathol, 2018, 11(7): 3656-3663.
[33]	Gu Z, Hou Z, Zheng L, et al. LncRNA DICER1-AS1 promotes the proliferation, invasion and autophagy of osteosarcoma cells via miR-30b/ATG5[J]. Biomed Pharmacother, 2018, 104: 110-118. DOI: 10.1016/j.biopha.2018.04.193. pmid: 29772430
[34]	孟爱霞, 官秀梅, 李桂芝, 等. miR-296-5p靶向PLK1调控PI3K/AKT通路诱导骨肉瘤细胞中的自噬并抑制上皮-间质转化[J]. 医学分子生物学杂志, 2022, 19(4): 287-294. DOI: 10.3870/j.issn.1672-8009.2022.04.004.
[35]	高世磊, 王家强, 姚伟涛, 等. miR-761通过调控肿瘤相关巨噬细胞极化对骨肉瘤MG63细胞上皮-间质转化的影响[J]. 吉林大学学报(医学版), 2024, 50(4): 978-988. DOI: 10.13481/j.1671-587X.202404012.
[36]	Yang Y, Ni WJ, Yang YD, et al. Research progress on N⁶-methyladenosine RNA modification in osteosarcoma: functions, mechanisms, and potential clinical applications[J]. Med Oncol, 2025, 42(3): 55. DOI: 10.1007/s12032-024-02597-x. pmid: 39853585
[37]	Zhang BY, Du XH, Fan YC, et al. DLX2 promotes osteosarcoma epithelial-mesenchymal transition and doxorubicin resistance by enhancing HOXC8-CDH2 axis[J]. iScience, 2023, 26(11): 108272. DOI: 10.1016/j.isci.2023.108272.
[38]	Wang ZY, Luo C, Wang HD, et al. CEACAM6 is associated with osteosarcoma metastasis and facilitates epithelial-mesenchymal transition in osteosarcoma cells[J]. Onco Targets Ther, 2018, 11: 3159-3166. DOI: 10.2147/OTT.S161807.
[39]	Benje M, Vitacchio T, Fritsche D, et al. Gene expression profiling and phenotypic characterization of circulating tumor cells derived from a murine osteosarcoma model[J]. Cancers (Basel), 2025, 17(7): 1210. DOI: 10.3390/cancers17071210.
[40]	Liu Y, Han Y, Guo Z, et al. Unveiling the role of the extracellular matrix in the osteosarcoma tumor microenvironment through integrated transcriptomics and experimental validation[J]. Cancer Gene Ther, 2025, 32(12): 1370-1384. DOI: 10.1038/s41417-025-00970-0.
[41]	Patraşcu AV, Ţarcă E, Lozneanu L, et al. The role of epithelial-mesenchymal transition in osteosarcoma progression: from biology to therapy[J]. Diagnostics (Basel), 2025, 15(5): 644. DOI: 10.3390/diagnostics15050644.
[42]	Xu Y, Bai YF, Yang F, et al. Decoding osteosarcoma from heterogeneity to precision therapy[J]. Discov Oncol, 2025, 17(1): 192. DOI: 10.1007/s12672-025-04256-7.
[43]	Cui Y, Wu Y, Jiang DY, et al. Single-cell and spatial transcriptomics reveal post-translational modifications in osteosarcoma progression and tumor microenvironment[J]. PLoS One, 2025, 20(10): e0333809. DOI: 10.1371/journal.pone.0333809.
[44]	Tang HJ, Cai YJ, Yang MX, et al. Single-cell and spatial transcriptomics reveals the key role of MCAM⁺ tip-like endothelial cells in osteosarcoma metastasis[J]. NPJ Precis Oncol, 2025, 9(1): 104. DOI: 10.1038/s41698-025-00896-8.
[45]	Zheng XJ, Liu X, Zhang X, et al. A single-cell and spatially resolved atlas of human osteosarcomas[J]. J Hematol Oncol, 2024, 17(1): 71. DOI: 10.1186/s13045-024-01598-7.
[46]	Liu J, Ren BH, He TM, et al. Engineering Osteosarcoma in vitro: from traditional models to biofabricated platforms for precision medicine[J]. ACS Omega, 2025, 10(46): 55219-55233. DOI: 10.1021/acsomega.5c09120.
[47]	Su WW, Li YY, Yang G, et al. Nanotechnology-driven strategies in osteosarcoma advances in treatment: immunotherapy and drug delivery[J]. Int J Nanomedicine, 2025, 20: 12913-12937. DOI: 10.2147/IJN.S549587.

基于上皮间质转化探讨骨肉瘤恶性生物学行为相关研究进展

Research progress on the malignant biological behavior of osteosarcoma based on epithelial-mesenchymal transition

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 47

相关文章 15

编辑推荐

Metrics

本文评价

[1]	洪燕芬, 魁国菊, 禹乐, 赖铭鸿, 黄江宾. 炎症负荷指数对非小细胞肺癌术后骨转移的预测价值[J]. 国际肿瘤学杂志, 2026, 53(7): 420-425.
[2]	李佳凝, 姚学敏, 王金云, 贾敬好, 孙国贵. NSCLC影像组学特征与临床特征构建的联合模型对其骨转移的预测效能研究[J]. 国际肿瘤学杂志, 2026, 53(6): 346-354.
[3]	孙晓宁, 何盼, 王宪, 姚淑娟. 卵巢癌中癌相关成纤维细胞的免疫调节机制与临床意义[J]. 国际肿瘤学杂志, 2026, 53(6): 376-380.
[4]	于欣静, 杨阳, 李殊瑶, 乔晓娟. CD300家族及其调控免疫细胞抗肿瘤作用机制的研究进展[J]. 国际肿瘤学杂志, 2026, 53(5): 296-300.
[5]	李一平, 唐桩, 欧阳苏瑞, 李进, 何敬东. 神经激肽-1受体拮抗剂在肺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(5): 306-310.
[6]	杨心茹, 曹莉莉. CC及CXC趋化因子在肿瘤微环境中的作用及治疗潜力[J]. 国际肿瘤学杂志, 2026, 53(4): 224-228.
[7]	屈振杰, 崔琴. lncRNA FGD5-AS1/miR-154-5p/WNT5A信号通路调控紫杉醇耐药胃癌细胞的增殖和转移机制研究[J]. 国际肿瘤学杂志, 2026, 53(3): 137-143.
[8]	张龙, 李建振, 张伟. 侵袭性伪足在肿瘤转移中的作用机制与治疗转化前沿[J]. 国际肿瘤学杂志, 2026, 53(2): 100-104.
[9]	李婷, 周琦, 张倩, 陈洁. 晚期非小细胞肺癌抗PD-1/PD-L1治疗耐药机制的研究进展[J]. 国际肿瘤学杂志, 2026, 53(1): 57-61.
[10]	王雨, 李袁飞, 郭云童. 免疫评分系统在胃癌中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(1): 62-64.
[11]	刘美, 胡玉崇, 李凤桐, 朝乐门, 柳檬, 亢琳琳. SHCBP1在恶性肿瘤中的作用机制及临床研究进展[J]. 国际肿瘤学杂志, 2025, 52(9): 583-586.
[12]	澈根, 乌日汗, 朱恬恬, 东丽. 非小细胞肺癌中cGAS-STING信号通路的作用机制及其靶向治疗策略[J]. 国际肿瘤学杂志, 2025, 52(9): 587-591.
[13]	宋美娇, 张锡泉, 沈庆林. 原发灶不明的转移性癌1例并文献复习[J]. 国际肿瘤学杂志, 2025, 52(9): 606-608.
[14]	张百红, 岳红云. 靶向肿瘤转移的新策略[J]. 国际肿瘤学杂志, 2025, 52(8): 528-531.
[15]	钟啸, 李步托, 王琳琳. ALK阳性NSCLC脑转移放疗的研究进展[J]. 国际肿瘤学杂志, 2025, 52(6): 374-378.